“These groundbreaking results offer hope for the FUS-ALS community and represent an exciting milestone in our efforts to transform the treatment of this rare, rapidly progressive and fatal form of ...
Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic ALS ...
Otsuka Pharmaceutical's ulefnersen met the primary endpoint of its Phase III FUSION trial in FUS-ALS, delivering the first statistically significant result from a placebo-controlled study targeting ...
– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. The program reflects Otsuka’s commitment to ...
– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Ulefnersen demonstrated a statistically significant ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. – Ulefnersen demonstrated a statistically significant ...
Otsuka Pharmaceutical Development & Commercialization, Inc. today announced the initiation of a global early access program (EAP) for ulefnersen, an investigational RNA-targeted medicine, for eligible ...
Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION ...
Michigan Republican faces pressure during heated debate on Trump's Canada tariffs Hayden Panettiere’s daughter appears in court alongside father Hockey Alberta warning of 'suspicious' tournament ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results